New fea­tures de­liver ad­di­tional sizes, ster­il­i­sa­tion/sani­ti­sa­tion com­pat­i­bil­ity


ACHIEV­ING high prod­uct pu­rity early in the man­u­fac­tur­ing process and im­prov­ing ef­fi­ciency and eco­nomics is im­por­tant to bio­phar­ma­ceu­ti­cal man­u­fac­tur­ers. In­creas­ing re­moval of im­pu­ri­ties like DNA and HCP dur­ing clar­i­fi­ca­tion im­proves the per­for­mance of down­stream cap­ture and pol­ish­ing steps. The 3M Em­p­haze AEX Hy­brid Pu­ri­fier meet these chal­lenges through re­duc­tion of cell de­bris, DNA and HCP at clar­i­fi­ca­tion to help im­prove down­stream process steps, prom­ises the de­vel­oper. The new Em­p­haze cap­sules are ster­il­i­sa­tion/ sani­ti­sa­tion com­pat­i­ble and can be used across var­i­ous aque­ous based bio­phar­ma­ceu­ti­cal pro­cesses, in­clud­ing vac­cine pu­rifi­ca­tion. Ad­di­tion­ally, the im­proved Em­p­haze AEX Hy­brid Pu­ri­fier prod­ucts now fea­ture two new lab­o­ra­tory cap­sules and one scale-up cap­sule that al­lows eval­u­a­tions at lab­o­ra­tory and scale-up vol­umes.

Em­p­haze AEX Hy­brid Pu­ri­fier prod­ucts com­bine three unique 3M tech­nolo­gies – ad­vanced poly­mer ma­te­ri­als, fine fi­bre non­wo­vens, and mem­branes

– to de­liver a syn­thetic clar­i­fy­ing prod­uct line con­tain­ing a novel an­ion ex­change non­wo­ven me­dia and a fine par­ti­cle, re­duc­tion mem­brane.

Newspapers in English

Newspapers from New Zealand

© PressReader. All rights reserved.